MD Biosciences ArthritoMab(TM) Antibody Cocktail Offers Improved Epitope Specificity For The Induction Of Arthritis

ZURICH, Switzerland, Sept. 12 /PRNewswire/ -- MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new and improved ArthritoMab(TM) Antibody Cocktail for the induction of arthritis. This monoclonal antibody cocktail, developed by Prof. Rikard Holmdahl and licensed to Morwell Diagnostics (parent company of MD Biosciences), offers many improvements over other arthritis inducing cocktails such as a flexible protocol design for the study of TLR dependent or independent disease pathology and severe arthritis observed in front and rear paws.
MORE ON THIS TOPIC